BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

317 related articles for article (PubMed ID: 33128812)

  • 1. Optimization of de novo belatacept-based immunosuppression administered to renal transplant recipients.
    Kirk AD; Adams AB; Durrbach A; Ford ML; Hildeman DA; Larsen CP; Vincenti F; Wojciechowski D; Woodle ES
    Am J Transplant; 2021 May; 21(5):1691-1698. PubMed ID: 33128812
    [TBL] [Abstract][Full Text] [Related]  

  • 2. De novo donor-specific antibodies in belatacept-treated vs cyclosporine-treated kidney-transplant recipients: Post hoc analyses of the randomized phase III BENEFIT and BENEFIT-EXT studies.
    Bray RA; Gebel HM; Townsend R; Roberts ME; Polinsky M; Yang L; Meier-Kriesche HU; Larsen CP
    Am J Transplant; 2018 Jul; 18(7):1783-1789. PubMed ID: 29509295
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Belatacept Combined With Transient Calcineurin Inhibitor Therapy Prevents Rejection and Promotes Improved Long-Term Renal Allograft Function.
    Adams AB; Goldstein J; Garrett C; Zhang R; Patzer RE; Newell KA; Turgeon NA; Chami AS; Guasch A; Kirk AD; Pastan SO; Pearson TC; Larsen CP
    Am J Transplant; 2017 Nov; 17(11):2922-2936. PubMed ID: 28544101
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Calcineurin inhibitor-free immunosuppression in pediatric renal transplantation: a viable option?
    Höcker B; Tönshoff B
    Paediatr Drugs; 2011 Feb; 13(1):49-69. PubMed ID: 21162600
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of an Early Switch to Belatacept Among Calcineurin Inhibitor-Intolerant Graft Recipients of Kidneys From Extended-Criteria Donors.
    Le Meur Y; Aulagnon F; Bertrand D; Heng AE; Lavaud S; Caillard S; Longuet H; Sberro-Soussan R; Doucet L; Grall A; Legendre C
    Am J Transplant; 2016 Jul; 16(7):2181-6. PubMed ID: 26718625
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-Term Outcomes after Conversion to a Belatacept-Based Immunosuppression in Kidney Transplant Recipients.
    Divard G; Aubert O; Debiais-Deschamp C; Raynaud M; Goutaudier V; Sablik M; Sayeg C; Legendre C; Obert J; Anglicheau D; Lefaucheur C; Loupy A
    Clin J Am Soc Nephrol; 2024 May; 19(5):628-637. PubMed ID: 38265815
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunosuppression with belatacept-based, corticosteroid-avoiding regimens in de novo kidney transplant recipients.
    Ferguson R; Grinyó J; Vincenti F; Kaufman DB; Woodle ES; Marder BA; Citterio F; Marks WH; Agarwal M; Wu D; Dong Y; Garg P
    Am J Transplant; 2011 Jan; 11(1):66-76. PubMed ID: 21114656
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and Efficacy Outcomes 3 Years After Switching to Belatacept From a Calcineurin Inhibitor in Kidney Transplant Recipients: Results From a Phase 2 Randomized Trial.
    Grinyó JM; Del Carmen Rial M; Alberu J; Steinberg SM; Manfro RC; Nainan G; Vincenti F; Jones-Burton C; Kamar N
    Am J Kidney Dis; 2017 May; 69(5):587-594. PubMed ID: 27889299
    [TBL] [Abstract][Full Text] [Related]  

  • 9. De novo belatacept in clinical vascularized composite allotransplantation.
    Cendales LC; Ruch DS; Cardones AR; Potter G; Dooley J; Dore D; Orr J; Ruskin G; Song M; Chen DF; Selim MA; Kirk AD
    Am J Transplant; 2018 Jul; 18(7):1804-1809. PubMed ID: 29723921
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An update on chemical pharmacotherapy options for the prevention of kidney transplant rejection with a focus on costimulation blockade.
    Kälble F; Schaier M; Schäfer S; Süsal C; Zeier M; Sommerer C; Morath C
    Expert Opin Pharmacother; 2017 Jun; 18(8):799-807. PubMed ID: 28460546
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Switching from calcineurin inhibitor-based regimens to a belatacept-based regimen in renal transplant recipients: a randomized phase II study.
    Rostaing L; Massari P; Garcia VD; Mancilla-Urrea E; Nainan G; del Carmen Rial M; Steinberg S; Vincenti F; Shi R; Di Russo G; Thomas D; Grinyó J
    Clin J Am Soc Nephrol; 2011 Feb; 6(2):430-9. PubMed ID: 21051752
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Posttransplant reduction in preexisting donor-specific antibody levels after belatacept- versus cyclosporine-based immunosuppression: Post hoc analyses of BENEFIT and BENEFIT-EXT.
    Bray RA; Gebel HM; Townsend R; Roberts ME; Polinsky M; Yang L; Meier-Kriesche HU; Larsen CP
    Am J Transplant; 2018 Jul; 18(7):1774-1782. PubMed ID: 29573335
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Experience with belatacept rescue therapy in kidney transplant recipients.
    Brakemeier S; Kannenkeril D; Dürr M; Braun T; Bachmann F; Schmidt D; Wiesener M; Budde K
    Transpl Int; 2016 Nov; 29(11):1184-1195. PubMed ID: 27514317
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Postdepletion Lymphocyte Reconstitution During Belatacept and Rapamycin Treatment in Kidney Transplant Recipients.
    Xu H; Samy KP; Guasch A; Mead SI; Ghali A; Mehta A; Stempora L; Kirk AD
    Am J Transplant; 2016 Feb; 16(2):550-64. PubMed ID: 26436448
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunosuppressive minimization with mTOR inhibitors and belatacept.
    Diekmann F
    Transpl Int; 2015 Aug; 28(8):921-7. PubMed ID: 25959589
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of Utilization and Clinical Outcomes for Belatacept- and Tacrolimus-Based Immunosuppression in Renal Transplant Recipients.
    Wen X; Casey MJ; Santos AH; Hartzema A; Womer KL
    Am J Transplant; 2016 Nov; 16(11):3202-3211. PubMed ID: 27137884
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ASP2409, A Next-Generation CTLA4-Ig, Versus Belatacept in Renal Allograft Survival in Cynomolgus Monkeys.
    Song L; Ma A; Dun H; Hu Y; Fujii Y; Kinugasa F; Oshima S; Higashi Y; Daloze P; Chen H
    Am J Transplant; 2017 Mar; 17(3):635-645. PubMed ID: 27598231
    [TBL] [Abstract][Full Text] [Related]  

  • 18. De Novo Belatacept in a Human Immunodeficiency Virus-Positive Kidney Transplant Recipient.
    Cohen EA; Mulligan D; Kulkarni S; Tichy EM
    Am J Transplant; 2016 Sep; 16(9):2753-7. PubMed ID: 27137752
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Utility of a fusion protein T-cell co-stimulation blocker Belatacept in heart transplant recipients: Real world experience from a high volume center.
    Oren D; Uriel M; Moeller CM; Valledor AF; DeFilippis EM; Lotan D; Colombo PC; Yuzefpolskaya M; Topkara VK; Clerkin KJ; Raikhelkar JK; Fried JA; Oh DKT; Bae D; Lin E; Theodoropoulos K; Naka Y; Takeda K; Choe J; Jennings DL; Majure D; Latif F; Sayer G; Uriel N
    Clin Transplant; 2024 Mar; 38(3):e15251. PubMed ID: 38504576
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-Term Outcomes in Belatacept- Versus Cyclosporine-Treated Recipients of Extended Criteria Donor Kidneys: Final Results From BENEFIT-EXT, a Phase III Randomized Study.
    Durrbach A; Pestana JM; Florman S; Del Carmen Rial M; Rostaing L; Kuypers D; Matas A; Wekerle T; Polinsky M; Meier-Kriesche HU; Munier S; Grinyó JM
    Am J Transplant; 2016 Nov; 16(11):3192-3201. PubMed ID: 27130868
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.